

Appendix A
Pending Claim Set as Renumbered by the Examiner

23. A method of treating non-insulin dependent diabetes mellitus comprising co-administering:
 - a) an effective dosage of a GLP-1 peptide agonist; and
 - b) an effective dosage of pioglitazone or rosiglitazone.
24. The method of Claim 23 wherein an effective dosage of pioglitazone is administered.
26. The method of Claim 23 wherein the GLP-1 agonist is a GLP-1 molecule.
27. The method of Claim 26 wherein the GLP-1 molecule is an analog of SEQ ID NO:1.
28. The method of Claim 26 wherein the GLP-1 molecule is a GLP-1 derivative.
29. The method of Claim 26 wherein the GLP-1 molecule comprises Valine, Glycine, Threonine, or Methionine at position 8.
30. The method of Claim 23 wherein the effective dosage of the GLP-1 agonist is in the range of about 5 to about 200 µg per day.
31. The method of Claim 26 wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 µg per day.

32. The method of Claim 27 wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 μ g per day.
33. The method of Claim 28 wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 μ g per day.
34. The method of Claim 29 wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 μ g per day.
35. The method of Claim 23 wherein the effective dosage of the GLP-1 agonist is in the range of about 20 to about 100 μ g per day.
36. The method of Claim 26 wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 μ g per day.
37. The method of Claim 27 wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 μ g per day.
38. The method of Claim 28 wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 μ g per day.
39. The method of Claim 29 wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 μ g per day.

40. The method of Claim 23 wherein the effective dosage of the GLP-1 agonist is in the range of about 30 to about 50 µg per day.
41. The method of Claim 26 wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.
42. The method of Claim 27 wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.
43. The method of Claim 28 wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.
44. The method of Claim 29 wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.
45. The method of Claim 23 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.
46. The method of Claim 26 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.
47. The method of Claim 27 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.
48. The method of Claim 28 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.

49. The method of Claim 29 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.
50. The method of Claim 23 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.
51. The method of Claim 26 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.
52. The method of Claim 27 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.
53. The method of Claim 28 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.
54. The method of Claim 29 wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.
55. The method of Claim 23 wherein the GLP-1 agonist is administered as a composition comprising a GLP-1 molecule at a concentration of between 10^{-12} M and 10^{-5} M.
56. The method of Claim 23 wherein the GLP-1 agonist is administered as a controlled release preparation.